Strategic Collaborations Vesta is well positioned to pursue strategic collaborations with pharma and CROs to develop stem cell derived model systems for drug discovery. Core assets include iPS and donor tissue derived models from liver, brain, biliary tree, and umbilical cords. The combination of strong IP and deep drug discovery expertise enables differentiated tools for lead discovery, target validation, and assay development. Target joint development agreements, IP licensing, or co branded tools with industry leaders.

IP Driven Licensing The robust IP portfolio can unlock licensing opportunities for stem cell models, media formulations, and discovery tools. Engage with licensing teams at large pharma and CROs to pursue milestone based deals and royalties. Emphasize exclusivity options and field or geography rights to maximize value.

Targeted Partner Network Identify channel partners among leading ecosystem players and CRO networks to serve as distributors or co developers for niche stem cell platforms. Position Vesta as a specialized provider that accelerates drug discovery workflows with ready to use model systems and validated assays. Explore partnerships with major suppliers and service providers to broaden reach.

Global Market Access Leverage the existing international branding and relationships to expand beyond local markets. Pursue international collaborations for joint development, regional distribution, and access to patient derived cell resources. Align with regulatory considerations and clinical translation opportunities to appeal to global customers.

Scale via Alliances With a lean team, Vesta can scale through strategic alliances that handle manufacturing, validation, and services at scale. Build a partner program and digital marketing efforts to reach prospective pharma and CRO customers. Use the online presence and professional materials to showcase IP and case studies.